Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

antibodies, patterns
Mo.A.273, Th.A.408 I, We.A. 143,
We.A.30 I5, We.C.3398
antibodies, saliva
MoC.1403, NoC. 1416, Mo.CI52 8,
Th. B.4 I155, Th.B.4 I58,1Th.[D.498 1I
Th.D.5004, We.B.3 I172, VW.B.3 174
antibodies, specific
No.A. 1014, Mo.A. 1058, Pub.A. I01 3,
Pub. B. I1080, T hA.40 14, Th. B.41I60,
Th. B.4299, Tu.A.20 I10, Tu.A.2099,
We.A.30 I15, We.B.3373, VhvA.4024,
We.B.3 172, No.A. 1009
antibody dependent enhancement
Mo.B. 1124, Tu.A.2007, We./\.3007,
We.A.301 3, We.A.3023
antibody response
Mo.A. 154, PubA. 10 1 0,Th.A.4084,
Th.B.4097, V.A.2 104, lo.8.22O7,
We.A.30 I16, We.A.30 I!, We.A.30 19,
We.A.302 1, We.A.392, We.8B.115,
We.B.294, We.B.337 I
antibody tests, SEE serologic tests
Mo.B. I178, Mo.B. 11I79, No.B. I1I84,
loC. 1499, No.C.2 I13, Pub.8. 1041,
Pub. B.1043, Pub.B. 1080, Pub.. 1379,
Th.A.40 I14, Tb.A.4026, Vh.A.4049.
Th.B.4 I 52,Th.D.5 I1I3, Tu.B.2 I66,
Tu.B.2 I 74jfu.D 2709, We.A.3045,
We.B.3 I78
antibody-dependent cellular
cytotoxicity (ADCC)
Tu.A.2056, We.A.30 13, We.A.3023
anticardiolipin antibody (ACA)
No.8. I1288, No.8. 1298,3T IvA.4086,
We.A.30 17, We.A.3039
antifungal agents, SEE also individual
No.B. I116, Mo.B. 1229, 10.8.4207
antigen presenting cells
TuB. I95,Tu.B.40 I
antigen receptors of T cells
Mo.A.39 I, Tu.A.20 I12, Tu.A.203 3,
We.A.3029, We.A.3050, We.A.3058
antigen specific immunotherapy
Mo.A. I 058,Th.B.4240, TI 6.B.4310,
Tu.A.272, Tu.A.282
antigenemia
Mo.A. I162, Mo.A.5 I12, Mo.8. 1176,
M o.8B.1219, Mo.B.1 226, MNo.B. 1376,
Th.A.392,Th.B.4 I1I8,368..4 197,
Th. B.4 I198, Th. B.4200,Tu. B.2 193,
We.C.3398
antinuclear antibodies (ANAs)
Th.A.4088
antisense therapy
Nb.A. 1010, No.A. 1082,
No.B. 1 I27Tu.A.280, We.A.275,
No.8.1 195
antituberculous drugs, SEE also
individual drugs
No.8. 139 I, Pub.B. I 086,Th.A.405 I,
Th.8.4304, Yh..4305,Th.8.4307,
We.B.336 I, We.B.3368
snxiety
r 'lo.B. I131I3, Pob.B. I1097, Th.C.4390,
1 h.C.46 I 4,Th.D.509 I,Io.B.2342,
VV'e.B.331 I,We.D.3618

art
No.8.1298, No.8. 17 1, No.D. I1855,
Th.C.45 I I,Th.C.452 I,Th.C.4565,
Th.D.5 I166, 3.D.2848,Tu.D.285 I,
foa.[.363, We.D.37 16
arthralgia
No.8. I1298, No.8.1I298, No.8. 17 1,
No. 8.1297
artificial insemination
Th.D.5099
artificial insemination
We.C.3528
aspergillosis
No.B. I1232, Tu.8.2 I 75, To.B.2 I196,
We.B.33 I16, We.8.332 I
astrocyte
No.D. I1878, We.A. 145
asymptomatic stage
No.A. 1022, No.8. 1386, No.8.424,
No.D. I1893, No.D. I 894,Th.C.4792,
T.A.2048, Y..2260, To.C.55 I,
VWe.A.3027, We.A.3028, We.A.3034,
We.B.3 I122, We.8.3256, We.B.3256,
We.8.3269, We.C.3 398
atovaquone
Th.A.4064, Tu.A.5 I 3, Tu.B. I1I6
attitudes, SEE also survey
No.C. 1593, No.C. 1600, No.D. 1691,
No.D. 1695, No.D. 1729, No.D. 1827,
No.D. 1869, No.D. 1919, No.D.247,
Pob.C.I1187, Pub.C.lI 194, Pob.C.12 12,
Pub.C. I1227, Pob.C. I123 I, Pob.C. 1275,
Pub.C. I1277, Pob.D. 1358, Pob.D. 1465,
Th.C.2 I 0,Th.C.4396,Th.C.4402,
3 h.C.4439, T IC.4439, Th.C.45 I12,
Tb C.4527, Th.C.4530,Th.C.4567,
3 h.C.4722,Th.C.4799,Th.D.445,
Th.D.5 I 23,Th.D.5 I 88,To.B.2 IS I,
3o.D.27 I I,T.D.2742,To.D.2838,
T.D.46 I, We.8.3 14 I, We.C.3486,
We.D.243, We.D.244, We.D.364 I,
We.D.3708, We.D.3854
autoimmune phenomena
No.8. 1288, No.8.1297, No.8. 1300,
Th.A.408 I, Fh.A.4082,Th.A.4083,
1 h.A.4084, Th.A.4085, Th.A.4086,
To.A.205 I, We.A.3039, We.A.304 I,
We.A.3045
autonomy
No.D. 1887, Pob.D. I1460, Th.C.4640,
T.B.2262,Tu.B.2338,To.B.54 I,T.D.2935,
We.D.3696, We.D.3868
autopsy
No.C. 1544, Pob.8. 1055, Pob.B. 1061,
Pub.B. I1076, Th.A.4048, 6.8. 1 82,
I-h.8.4230, Th.B.423 I
azidothymidine, SEE zidovudine
N o.8B. 175, Tu.A.2006, Tu.8B.21I I5
azidouridine (AzdU, CS-87)
Th.C.4537
AZT, SEE zidovudine
No.A. 1068, No.A. 1079, No.A. I 105,
No.8.1 141,NMo.8.I 142, No.8. 1191,
No.8.295, No.C.325, Pob.A. 1030,
T hB. I185, Th.8.290, Th.B.4 I178, Th.B.4347,
TVh.C.4822, To.A.265, Tu. B.2 132,
u.B.2 I156, T.B.232 I, We.A.3006,

No.8.131 1, No.8.1323, No.8.1379,
No.C. I1674, Pob.B. 1087, Pob.B. 1088,

Th.A.4080, Th.B.4 I181, Th. B.4 189,
Th.B.4 I190, Th.B.428 I, 16.8.4 346,
Th.C.220, To.B. I80, Ti.B.1I8 I, u.B.2 I54,
To.B.2 I59,l u.B.2 I 5,Tu.B 2176,
To.B.2 I 77,To.B.2 178,..? 8.2I1,
Tu.C.2656,Tu.C.2688, We 8.1 15,
We.B.3204, VWe..3208, We.8. 32 10,
We.B.321 I,We.B.3 297, We 8.33 18,
We.B.33 19, We.B 332 I,We.C.3423
behaviour change
No.C. 1489, No.C. 1607, No.C.465,
No.D. 1685, No.D. 1701, No.D. 1704,
No.D. 1717, No.D. 1725, No.D. 1753,
No.D. 1755, No.D. I1757, No 1). 1758,
No.D.1765, No.D.l1773, No.D.I1779,
No.D. 1780, No.D. 1795, No.D. 1800,
No.D. 1803, No.D. 1818, No.D. 1823,
NoD. 1826, No. D.1829, No.D. 1831,
No.D. I1847, No.D. I1858. No.D. 1859,
No.D. 1863, No.D. 1873, No.D. 1875,
No.D. 1879, No.D. 1882, No.D. 1943,
No.D.244, No.D.36 I, No.D.484,
No.D.580, No.D.58 1, Pub.B. 1078,
Pub.C. I 11I6, Pob.C. I1I64, Pob.C. I1I67,
Pub.C.I1168, Pub.C.I1169, Pub.C.I1183,
Puh.C. I 194, Pob.C. I1202, Pob.C. 12 17,
Pub.C. I1224, Pob.C. I1239, Pob.C. I1249,
Pub.C. I1252, Pob.C. I1254, Pub.C. I126/,
Pob.C. 128 I, Pub.D. I1298, Pob.D. 131 8,
Pub.D. I1325, Pub.D. I1326, Pub.D. I1333,
Pub.D. 1335, Pub.D. I1337, Pub.D. 1341,
Pub.D. I1348, Pub.D. I1369, Pub.D. I1372,
Pub.D. I1378, Pub.D. I1383, Pob.D. 14 10,
Pub.D. 1445, Pub.D. 1449, Pub.D. 1453,
Pub.D. 1456, Pub.D. 1469, Pb.1 4 71,
Puh.D. 1482, Pub.D. 1486, Pob.D I1406.
Th.B.4243,Th.B.4254,-Vh.C.2 I13,
Th.C.422, Th.C.424, Tb.C.436 I,
Th.C.4375, Th.C.4380,3 h.C.4409,
Th.C.4430,Th.C.4435,-T1h.C.4458,
Th.C.4462, Th.C.4464, Th.C.4469,
Th.C.448 I,Th.C.4492,Th.C.4580,
Th.C.4603, Th.C.4667,1-h.C.4682,
Th.C.47 I15, Th.C.4724, 33.C.4725,
Th.C.4739,T6.C.4765, Th.C.47 73,
Th.C.4786,Th.C.4839,Th.C.484 I,
Th. D.240, Th. D.462, Th. D49 85,
Th. D.5009,i16. D.50I16, Yh. D.5049,
Th.D.5095,Th.D.5 139, V 6.D.5 I140,
Th.D.5 I 48,Th.D.5 I 97,Tu.B.2 148,
Tu.C.239 I,Tu.C.24 I 6, u.C.2492,
Tu.C.2496,Tu.C.25 I 0,Tu.C.2559,
Tu.C.2659,Tu.C.2669,Tu.C.330, Tu.C.452,
Tu.C.453,Tu.C.454,Tu.C.570,Tu.D.2 707,
Tu.D.27 I I,Tu.D.274 I, Tu.D.2770,
Tu. D.2778, Tu. D.2804, Tu. D.2806,
Tu.D.28 I 2,Tu.D.2860,3u.D.286 I,
Tu. D.2862, Tu. D.2864, -u. D.2875,
Tu. D.2878, Tu. D.2886, Tu. D.2904,
Tu. D.29 I16, Tu. D.2929, Ta. D.2964,
Tu.D.365,Tu.D.47 I,Tu.D.473,3u.D..4/5,
Tu.D.48 I, We.C.202, We.C.205,
We.C.349 I, We.C.3507, We.C.35 12,
We.C.35 I13, We.C.3524, We.C.3527,
We.C.3557, We.C.3560, We.C.3570,
We.C.580, We.D.3743, We.D.3 754,
We.D.3 768, We.D.3772, We.D 37/5,

We.C.35 I13, We.D.3775, We.D.3804,
We.D.38 10

behaviour; SEE also sexual behaviour
No8.13(11, No C. I,498, No C I1509,
No.C.1I6 10, NMo C I6301 NoC 1670.
No31 6 91, N..I/I2, N013. 1724,
Mo.D.I1874, N.11876, P1(..Io I,
No.D.1919, MNo.3"0(,1lo6. 11 31,
Pub.C. I I87, Pub.C.. I I9'. 1203/,
Pub.D. 1366, Pub.I 394 Po1.') 31103,
1b8h.'1264,lv(.43"71,11 (-.113,
1.C.4439,lI.C.453,-16h.3 183
Th. D.4928, TI..50,11,1Th6[.5 I813,
Fu. B.2 171,1Iu.(,.21483, b uC.199
ofX 251 I, 333.2(. 60i( 1,
Iu.3).26S ', lo 1(2 '2 3, 1lo[;.8I
We.B.3 1509,A33. (.3153WV _.1).130/
beliefs
No.8. I183, No.13..I1686, Plo 3),.I687.
NoD. 1691, No.1I696, No 13. 1818.
No.33.1830, NoM31921, NM I).1125,
No.13.463, Pub.C. I1164, Pub 3.. 1173,
Pub C. 1212, PobLI. 129 1, Poll[).I1359,
Pub.[.. 11/5,. 'oLE) 1378,ILu1.[:1I1439,
Pobl. I187, Thv. 196,1Th.(.210),
Y6.C.'13 73, 161)C.4436, TIC (( 6 31I.
I1-1.0:.4745, 16.Cl /1/. (6.1).453.
111)3.455, 36.13.49 16. 111.D.49'29,
1 613.5 15, 1-..5 123,1 H13' 2)'.
Ivv.B.2 I S Ii(.(.2531, lo.l 27331,
3u.D.27 12, lu.[.277 I, (((.2 78.
Tu.D.28 I5,lL.[).2832, hL.D.2833,
lul 2834,3u.3.2838,[1([1).27830,
Lu.D.2859, Iu.3.286 I, L.[.)86I,
Tu.D).2867, 3u.).364. W'.PB31 b9
VWe C. 122, vV(C. 34/ I. V2 1. 360
We33.3610,Ve.[l.3/l I,,, oIL03895
benzalkonium chloride
Nof..053 8..2283)
beta carotene
Mo.A. I045, I(AL/.1I058. i'S.A. I LN,
Mo.A. I1S3,3 I.B.4299,lLJ..101I,
T-1.8.2275, bu.C 2588, We.. (LI 3,
We.B. I85,VWe..325 i
beta -2-microglobu lirr
Mo.A. I1003, No.33. I312. Pub.A. I1026,
Th.8.4285. IL 6.1295. 1.C.22-,1(1 8.190,
3u.8.22 33, lo 8.2318, lul.13 3,
beta-glucuronidase
Iou.C.2688
biochemical abnormalities
No.A.I1101, 3u..2233, (u.S.,2(68
biological response modifiers (BRM)
1 u.A.2 70, We/I. 3081I
biopsy
No.B.123),NM.3.I'89,I'olD.l/70.
No.D. 180 3. P,(6.B.I3)05, ('Hil1252,
Th.A.2 /3,1 15433256, IIlh.123'.
I 6.8.420 1,1 1.3.243,31 h3) "043,
Tu.B.23 I I, lo C.230'1 u6C/400,
To.C.210'1, H.C.2.11 0, b.C.2'18 3.
u.L.2755, l[,3)57, I.I)000,
We'.8.3234,V'We8.3286. VA.1)32398,
Wo.B.3299, We.3.3 320 VVL'L( 335 i,
WL.C.348 7, We. C, 3501.'e133)313
blastomycosis
We.B.322, W'.I)A.13 3
bleach use among IDL~s

0
U
(1
0
U
a)
a)
C
0
0
-10
C
a)

477